Gastrointestinal stromal tumor natural history: Difference between revisions
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
==Prognosis== | ==Prognosis== | ||
At the time of clinical presentation, the prognosis appears to be influenced by genetic events other than kinase mutations, although a particular kinase mutation may help to define the initial clinical course of a GIST. Based on retrospective studies from time periods that predated the clinical use of kinase inhibitors, current recommendations for assessing the risk of progression for a newly diagnosed primary GIST rely on three parameters | At the time of clinical presentation, the prognosis appears to be influenced by genetic events other than kinase mutations, although a particular kinase mutation may help to define the initial clinical course of a GIST. Based on retrospective studies from time periods that predated the clinical use of kinase inhibitors, current recommendations for assessing the risk of progression for a newly diagnosed primary GIST rely on three parameters: | ||
Mitotic index (mitoses per 50 high-power fields) | *Mitotic index (mitoses per 50 high-power fields) | ||
Tumor size | *Tumor size | ||
Tumor location | *Tumor location | ||
{{reflist|2}} | {{reflist|2}} | ||
<ref>{{Cite web | title =Risk Assessment and Prognosis | |||
[[Category:Disease]] | | url =http://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq#section/_1 }}</ref>[[Category:Disease]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
Revision as of 17:58, 2 September 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
|
Gastrointestinal stromal tumor Microchapters |
|
Differentiating Gastrointestinal stromal tumor from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Gastrointestinal stromal tumor natural history On the Web |
|
American Roentgen Ray Society Images of Gastrointestinal stromal tumor natural history |
|
Directions to Hospitals Treating Gastrointestinal stromal tumor |
|
Risk calculators and risk factors for Gastrointestinal stromal tumor natural history |
Overview
Prognosis
At the time of clinical presentation, the prognosis appears to be influenced by genetic events other than kinase mutations, although a particular kinase mutation may help to define the initial clinical course of a GIST. Based on retrospective studies from time periods that predated the clinical use of kinase inhibitors, current recommendations for assessing the risk of progression for a newly diagnosed primary GIST rely on three parameters:
- Mitotic index (mitoses per 50 high-power fields)
- Tumor size
- Tumor location